1	Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis:
2	A systematic review and meta-analysis
3	
4	Rubeshan Perumal ^{1,2} *, Neda Bionghi MD ^{*3} , Camus Nimmo ⁴ , Marothi Letsoalo ¹ , Matthew J. Cummings ⁵ ,
5	Madeleine Hopson MD ³ , Allison Wolf ⁵ , Shamim Al Jubaer ⁶ , Nesri Padayatchi ¹ , Kogieleum Naidoo ¹ ,
6	Michelle H. Larsen# ⁶ , Max O'Donnell# ^{1,5,7}
7	
8	^{1.} CAPRISA MRC-HIV-TB Pathogenesis and Treatment Research Unit, Centre for the AIDS Programme
9	of Research in South Africa, Durban, South Africa
10	^{2.} Division of Pulmonology and Critical Care, Department of Medicine, University of KwaZulu-Natal,
11	Durban, South Africa
12	^{3.} Department of Medicine, Columbia University Irving Medical Center and New York-Presbyterian
13	Hospital, New York, NY, USA
14	^{4.} Francis Crick Institute, London, UK
15	^{5.} Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Columbia
16	University Irving Medical Center, New York, NY, USA
17	^{6.} Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA
18	^{7.} Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical
19	Center, New York, NY, USA
20	
21	* These authors contributed equally to the manuscript.
22	# These authors contributed equally to the manuscript.
23	
24	Main text: 1251
25	Figures: 1
26	
27	Keywords: Emergent-resistance, acquired-resistance, <i>Rv0678, mmpR5,</i> bedaquiline-resistant TB

28 Abstract

29 Rationale

Bedaquiline is a novel antimycobacterial agent for drug-resistant tuberculosis (DR-TB) and is classified
 as a World Health Organization (WHO) Group A drug due to its excellent clinical efficacy, high
 bactericidal activity, and potent sterilizing effect. Baseline and treatment-emergent bedaquiline
 resistance have been described but prevalence and incidence have not been reported, leading to gaps
 in the knowledge required to design strategies to optimize MDR-TB clinical outcomes and prevent the
 amplification of bedaquiline resistance.

36

37 Methods

We performed a systematic review and meta-analysis to estimate the frequency of, and mutations associated with, baseline and acquired (treatment-emergent) bedaquiline resistance in clinical *Mtb* isolates. Pooled estimates of bedaquiline resistance were generated by proportional meta-analysis in R version 4.2.2 using dmetar, metafor and meta packages. Resistance associated variants associated with prevalent and incident bedaquiline resistance were identified.

43

44 Results

Data from 14 studies were included; 14 and 9 studies reported on pre-treatment and acquired
bedaquiline resistance, respectively. The pooled prevalence of pre-treatment bedaquiline resistance
was 2.4% (95% Cl 1.7 – 3.5), with significant heterogeneity across all studies (*l*² 66%, p<0.01). The
pooled prevalence of treatment-emergent bedaquiline resistance was 2.1% (95% Cl 1.4 - 3.0), with no
significant heterogeneity across the included studies (*l*² 0%, p=0.97).

50

51 Discussion

We found a concerning frequency of bedaquiline resistance present at baseline and acquired during
treatment. Urgent strategies are required to mitigate further resistance to this crucial drug.

- 54
- 55
- 56

57	Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis:
58	A systematic review and meta-analysis
59	
60	Bedaquiline is a novel antimycobacterial agent for drug-resistant tuberculosis (DR-TB) and is classified
61	as a World Health Organization (WHO) Group A drug due to its excellent clinical efficacy, high
62	bactericidal activity, and potent sterilizing effect.(1) The introduction of bedaquiline into treatment
63	regimens has enabled short-course all-oral multidrug-resistant TB (MDR-TB) regimens and the
64	shortening of drug-susceptible TB treatment.(2, 3)
65	
66	Bedaquiline targets F_1F_0 -ATP synthase to impair <i>Mycobacterium tuberculosis</i> (<i>Mtb</i>) ATP synthesis and
67	exerts other incompletely characterized bactericidal effects.(4) Variants in the target <i>atpE</i> and <i>atpB</i>
68	genes and off-target mutations in <i>mmpR5, mmpL5,</i> and <i>pepQ</i> have been associated with bedaquiline
69	resistance.(5, 6) We performed a systematic review and meta-analysis to estimate the frequency of,
70	and mutations associated with, baseline and acquired (treatment-emergent) bedaquiline resistance in
71	clinical <i>Mtb</i> isolates.
72	
73	The study protocol was registered in PROSPERO (CRD42022346547) and the PRISMA guidelines were
74	followed for reporting of the review methods and findings. Systematic searches of MEDLINE/PubMed,

75 Cochrane Central Register of Clinical Trials, and EMBASE were conducted through February 2023 for 76 publications on phenotypic resistance of bedaquiline. We included studies which reported clinical *Mtb* 77 isolates with bedaguiline resistance via minimum inhibitory concentration (MIC) values from patients 78 with at least rifampicin-resistant TB. Given the suboptimal positive predictive value of resistance-79 associated variants for phenotypic resistance, our study only evaluated phenotypic resistance as 80 defined by MIC thresholds. We excluded studies with MIC cutoffs inconsistent with WHO cutoffs, in vitro Mtb isolates not obtained from patients, or ≤ 3 patients/isolates. Phenotypic bedaguiline 81 82 resistance was defined by critical concentrations of 12µg/ml by MGIT method or 0.252µg/ml by broth 83 microdilution or 7H11 agar proportion method. Acquired bedaquiline resistance was defined as the 84 absence of phenotypic resistance before treatment and demonstration of phenotypic resistance on at 85 least one occasion during bedaquiline treatment (Table S1). Publication bias was evaluated using

funnel plots and methodological quality was assessed by the tool proposed by Hoy *et al.*(7) We
performed a proportional meta-analysis in R version 4.2.2 using dmetar, metafor and meta packages.
Paired MIC and resistance-associated variant (RAV) data were presented by scatterplots. Detailed
methods are available in the Supplementary File.

90

The systematic search identified 180 articles for assessment: 37 were duplicates, 47 did not meet 91 92 inclusion criteria, and 82 were excluded because they were in vitro studies, review papers, case 93 reports, used non-standardized MIC thresholds, did not distinguish between baseline and treatment-94 emergent resistance, contained overlapping data with another study, or had no retrievable full text 95 (Figure S1). The remaining 14 studies were included, comprising four randomized controlled trials and 96 10 cohort studies, emanating from five continents (Table S2). (5, 6, 8-19) In both baseline and during-97 treatment analyses there was evidence of significant positive publication bias. For the baseline 98 analysis, 13 studies were rated as low risk of bias, and one study as moderate risk of bias. For the 99 during-treatment analysis, three studies were rated as low risk of bias, and six studies as moderate risk of bias (Tables S3 and S4). 100

101

102 Fourteen studies, with a pooled sample of 9975 isolates, contributed to the estimate of baseline 103 bedaquiline resistance. Nine studies, with a pooled sample of 1912 isolates, contributed to the 104 estimate of treatment-emergent bedaguiline resistance. The pooled prevalence of baseline bedaquiline resistance was 2.4% (95% CI 1.7 – 3.5), with significant heterogeneity across all studies (I^2 105 106 66%, p<0.01) (Figure 1, Panel A). The pooled prevalence of treatment-emergent bedaquiline resistance 107 was 2.1% (95% CI 1.4 - 3.0), with no significant heterogeneity across the included studies (I^2 0%, 108 p=0.97) (Figure 1, Panel B). In the sensitivity analyses, no between-group differences were seen based 109 on the quality of the studies (low versus moderate risk of bias).

110

We identified 141 RAVs across all isolates in the included studies, comprising 71 unique RAVs at 58 unique sites. Four RAVs were mapped to the promoter region of the Mtb genome, 19 were mapped to the dimerization domains, and 42 were mapped to the DNA binding region. The complete list of RAVs and associated MICs is presented by scatterplot (**Figure 1, Panels C and D**). Treatment-emergent RAVs

were significantly more likely to be associated with phenotypic resistance than pre-treatment RAVs
[21/35 (60.0%, 95% CI 42.9 - 77.7) vs 24/97 (24.7%, 95% CI 15.8 - 33.7)].

117 The high degree of heterogeneity and publication bias suggests that our pooled estimate of baseline

118 bedaquiline resistance (2.4%, 95% Cl 1.7 – 3.5) may overestimate the true prevalence in clinical

settings. However, the two included studies which involved comprehensive national surveillance of all

120 patients initiating treatment for MDR-TB produced reliable estimates of pre-treatment bedaquiline

- resistance of 3.2% and 3.6% in Germany and South Africa, respectively.(8, 17) These levels of pre-
- treatment bedaquiline resistance likely reflect high rates of person-to-person community transmissionof bedaquiline-resistant TB.
- 124

We found a concerning pooled prevalence of acquired bedaquiline resistance during treatment – 2.1% (95%Cl 1.4 –3.0%). Our estimate is concordant with a previous systematic review which reported a frequency of phenotypic acquired bedaquiline resistance of 2.2%.(20) The low heterogeneity among included studies reflects the systematic evaluation of serial cultures from all patients treated for MDR-TB, ranging from weekly to alternate months until culture conversion. This approach avoided the spuriously high estimates of acquired bedaquiline resistance reported in studies that only performed serial phenotypic DST in patients with evidence of treatment failure.(21)

132

133 As mmpR5 (Rv0678) mutations are associated with cross-resistance to clofazimine and bedaquiline, 134 prior exposure to clofazimine may have contributed to the high levels of pre-treatment bedaguiline 135 resistance identified in settings with limited prior use of bedaquiline. As a WHO group B drug, 136 clofazimine has been increasingly used as part of shortened MDR-TB regimens globally. Bedaquiline 137 has a relatively long elimination half-life, estimated at around 5.5 months, rendering it particularly 138 vulnerable to acquired resistance when treatment is interrupted. For this reason, high levels of 139 adherence support, patient tracking, and robust novel treatment regimens with a high barrier to 140 resistance are necessary to mitigate the risk of acquired resistance. In addition, bedaquiline exhibits 141 sub-optimal penetration into caseous necrotic lesions exposing it to intralesional PK-PD mismatch.(22) 142 Few MDR-TB drugs offer adequate protection against bedaquiline resistance, which is an increasingly 143 important consideration when constructing an MDR-TB regimen.(8)

Bedaquiline received US Food and Drug Administration accelerated approval in 2012 and by 2014 – the 144 145 first case of bedaquiline-resistant TB was reported in a Tibetan refugee following treatment with a 146 bedaquiline-containing regimen.(23) Between 2015 and 2019, there were an estimated 300 cases of 147 bedaquiline-resistant TB cases in South Africa alone.(17) We are reminded that the prevalence of 148 rifampicin resistance was initially ~12 per 1000 patients shortly after roll out of rifampicin, but 149 amplified to ~300 per 1000 patients currently. (24, 25) A Markov decision modelling exercise estimated 150 the prevalence of bedaquiline resistance increasing to 588 per 1000 patients with more widespread 151 bedaguiline rollout.(26)

152

153 As we prepare for the mass rollout of bedaguiline-containing short-course regimens for the treatment 154 of MDR-TB, National TB Programmes will require substantial strengthening to avoid escalating levels of 155 bedaquiline resistance, ensuing surges in treatment failure and relapse, a growing dependence on 156 complex salvage regimens, and treatment destitution. Central to reducing the threat of bedaguiline-157 resistant TB epidemic is the need for a rapid diagnostic test to detect bedaquiline resistance. Research 158 to better understand the genetics of resistance as well as investment in rapid phenotypic methods 159 such as microscopic observation of drug susceptibility and reporter mycobacteriophages may be 160 required. To date, the development of a rapid molecular diagnostic assay has been severely 161 constrained by the poor phenotypic-genotypic concordance of resistance profiling for bedaquiline. In 162 parallel, as bedaguiline-based regimens are implemented, national and supra-national bedaguiline 163 resistance surveillance activities must be escalated as a critical early warning system.

164

165 **Competing interests**

166 The authors declare that they have no competing interests.

167

168 **Data availability**

169 Materials related to this review are available from the authors upon request.

- 170
- 171
- 172

173 References

Olayanju O, Limberis J, Esmail A, Oelofse S, Gina P, Pietersen E, et al. Long-term bedaquiline related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa.
 The European respiratory journal. 2018;51(5).

World Health Organisation. Rapid communication: key changes to the treatment of drug-resistant tuberculosis. Geneva; 2022.

1793.Paton NI, Cousins C, Suresh C, Burhan E, Chew KL, Dalay VB, et al. Treatment Strategy for180Rifampin-Susceptible Tuberculosis. The New England journal of medicine. 2023;388(10):873-87.

Mackenzie JS, Lamprecht DA, Asmal R, Adamson JH, Borah K, Beste DJV, et al. Bedaquiline
 reprograms central metabolism to reveal glycolytic vulnerability in Mycobacterium tuberculosis.
 Nature communications. 2020;11(1):6092.

184 5. Nimmo C, Millard J, van Dorp L, Brien K, Moodley S, Wolf A, et al. Population-level emergence
185 of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant
186 tuberculosis in southern Africa: a phenotypic and phylogenetic analysis. Lancet Microbe.

187 2020;1(4):e165-e74.

Kaniga K, Hasan R, Jou R, Vasiliauskienė E, Chuchottaworn C, Ismail N, et al. Bedaquiline Drug
 Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective
 In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB
 Isolates. J Clin Microbiol. 2022;60(1):e0291920.

Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in prevalence
studies: modification of an existing tool and evidence of interrater agreement. Journal of clinical
epidemiology. 2012;65(9):934-9.

Andres S, Merker M, Heyckendorf J, Kalsdorf B, Rumetshofer R, Indra A, et al. Bedaquiline Resistant Tuberculosis: Dark Clouds on the Horizon. American journal of respiratory and critical care
 medicine. 2020;201(12):1564-8.

Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of Highly
 Drug-Resistant Pulmonary Tuberculosis. The New England journal of medicine. 2020;382(10):893-902.
 Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, et al. Randomized pilot
 trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term
 outcome, tolerability, and effect on emergence of drug resistance. Antimicrobial agents and
 chemotherapy. 2012;56(6):3271-6.

11. Guglielmetti L, Jaspard M, Le Dû D, Lachâtre M, Marigot-Outtandy D, Bernard C, et al. Long term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. The
 European respiratory journal. 2017;49(3).

12. Ismail NA, Omar SV, Joseph L, Govender N, Blows L, Ismail F, et al. Defining Bedaquiline
Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective
Cohort Study. EBioMedicine. 2018;28:136-42.

210 13. Kempker RR, Mikiashvili L, Zhao Y, Benkeser D, Barbakadze K, Bablishvili N, et al. Clinical

211 Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-

212 Containing Regimens. Clinical infectious diseases : an official publication of the Infectious Diseases

Society of America. 2020;71(9):2336-44.
Liu Y, Gao M, Du J, Wang L, Gao J, Shu W, et al. Reduced Susceptibility of Mycobacterium

tuberculosis to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical

Outcomes in China. Clinical infectious diseases : an official publication of the Infectious Diseases
 Society of America. 2021;73(9):e3391-e7.

218 15. Veziris N, Bernard C, Guglielmetti L, Le Du D, Marigot-Outtandy D, Jaspard M, et al. Rapid

emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past
 errors. The European respiratory journal. 2017;49(3).

16. Villellas C, Coeck N, Meehan CJ, Lounis N, de Jong B, Rigouts L, et al. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use

of clofazimine or bedaguiline. The Journal of antimicrobial chemotherapy. 2017;72(3):684-90.

17. Ismail NA, Omar SV, Moultrie H, Bhyat Z, Conradie F, Enwerem M, et al. Assessment of

epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in
 patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. The
 Lancet infectious diseases. 2022;22(4):496-506.

18. Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, et al. Bedaquiline Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. The New England journal of medicine.
 2022;387(9):810-23.

19. Wu SH, Chan HH, Hsiao HC, Jou R. Primary Bedaquiline Resistance Among Cases of DrugResistant Tuberculosis in Taiwan. Frontiers in microbiology. 2021;12:754249.

233 20. Mallick JS, Nair P, Abbew ET, Van Deun A, Decroo T. Acquired bedaquiline resistance during the 234 treatment of drug-resistant tuberculosis: a systematic review. JAC Antimicrob Resist.

235 2022;4(2):dlac029.

236 21. Ghodousi A, Rizvi AH, Baloch AQ, Ghafoor A, Khanzada FM, Qadir M, et al. Acquisition of Cross 237 Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan.

Antimicrobial agents and chemotherapy. 2019;63(9).

239 22. Sarathy JP, Zuccotto F, Hsinpin H, Sandberg L, Via LE, Marriner GA, et al. Prediction of Drug
240 Penetration in Tuberculosis Lesions. ACS Infect Dis. 2016;2(8):552-63.

23. Somoskovi A, Bruderer V, Homke R, Bloemberg GV, Bottger EC. A mutation associated with
clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. The
European respiratory journal. 2015;45(2):554-7.

24. Loutet MG, Davidson JA, Brown T, Dedicoat M, Thomas HL, Lalor MK. Acquired Resistance to
245 Antituberculosis Drugs in England, Wales, and Northern Ireland, 2000-2015. Emerging infectious
246 diseases. 2018;24(3):524-33.

247 25. Stottmeier KD. Emergence of rifampin-resistant Mycobacterium tuberculosis in Massachusetts.
248 The Journal of infectious diseases. 1976;133(1):88-90.

26. Kunkel A, Cobelens FG, Cohen T. Tradeoffs in Introduction Policies for the Anti-Tuberculosis
Drug Bedaquiline: A Model-Based Analysis. PLoS medicine. 2016;13(10):e1002142.

251

252 Figure 1. Pooled prevalence of baseline (Panel A) and treatment-emergent (Panel B) bedaquiline

resistance in patients with drug-resistant TB. Baseline (Panel C) and treatment-emergent (Panel D)

254 resistance-associated variants and associated minimum inhibitory concentrations. Solid black lines

255 represent intermediate or resistant MICs, dashed lines represent susceptible MICs, and dotted lines

are RAVs that are associated with both susceptible and intermediate/resistant MICs.

